VA-DXC-TECHNOLOGY
2.1.2020 10:02:09 CET | Business Wire | Press release
Luxoft , a DXC Technology Company (NYSE: DXC), today in collaboration with LG Electronics, Amazon and Mapbox unveiled Luxoft HALO, the company’s latest shared mobility concept featuring a revolutionary digital, consumer-grade in-vehicle experience. Luxoft HALO will be formally debuted at CES® 2020, Jan. 7-10, 2020, Las Vegas, NV.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200102005099/en/
At home, consumers expect their digital experiences to be simple, convenient and accessible at any time across a range of devices. Increasingly, consumers also expect access to their favorite content and services, in the vehicle and on the go.
Luxoft HALO shared mobility concept demonstrates how all consumers’ mobility needs can be seamlessly integrated with their personal digital lifestyle.
”Together with our key partners, we can now deliver a complete, highly personalized and intelligent in-vehicle consumer-grade experience, powered by webOS Auto, the platform for shared and intelligent mobility,” said Vildan Hasanbegovic, director of partnerships and head of marketing at Luxoft Automotive. ”It’s an open platform that delivers, with exceptional quality, an existing ecosystem of intelligent services and dynamic content — from in-vehicle infotainment to connected video streaming services and more — that is increasingly becoming an essential part of consumers‘ personal digital lifestyles.”
Luxoft can already deploy webOS Auto to large-scale series production systems, including:
- Rear Seat Entertainment (RSE) for traditional needs;
- Rear Seat Entertainment (RSE) with ride-hailing mode;
- Cabin display for ride-hailing systems; and
- Center stack display for ride-hailing systems.
Partner Innovations Showcased in Luxoft HALO
LG Electronics and webOS Auto
webOS Auto is an open and ideal platform for shared and intelligent mobility. webOS Auto provides features, and functionality, and incorporates all essential components such as multimedia processing, multi-display control, connectivity, security, offering improved comfort and convenience to passengers.
Alexa Auto
Alexa already helps you simplify and organize your life at home – now you can take her with you on the go with Alexa Auto. Alexa can help you play music, get directions, place calls, listen to audiobooks, control your smart home, and more, with just your voice – so you can keep your hands on the wheel and eyes on the road. Alexa is already available in dozens of vehicles from leading automakers, and Amazon has released services like the Alexa Auto SDK that make it easy for automakers and suppliers to integrate Alexa directly into their infotainment system. To learn more, visit amazon.com/alexa-auto/ .
Mapbox
Mapbox is a live location data platform powering maps and navigation experiences for mobile, web, gaming, and automotive. Mapbox maintains SDKs for developers building for webOS Auto, Android, iOS, Unity 3D, and web, and APIs for rendering maps and performing spatial functions. Every month, over 150,000 developers build with Mapbox. Over 45,000 mobile apps are powered by Mapbox SDKs. Applications and platforms built by developers using Mapbox reach more than 600 million monthly active users.
Luxoft at CES® 2020
Visit Luxoft at CES for a personal, hands-on experience of Luxoft HALO and to experience the future of shared and intelligent mobility; booth #6928, North Hall, Tech East, Las Vegas Convention and World Trade Center.
About Luxoft
Luxoft, a DXC Technology Company, (NYSE: DXC), is a digital strategy and software engineering firm providing bespoke technology solutions that drive business change for customers the world over. Luxoft uses technology to enable business transformation, enhance customer experiences, and boost operational efficiency through its strategy, consulting, and engineering services. Luxoft combines a unique blend of engineering excellence and deep industry expertise, specializing in automotive, financial services, travel and hospitality, healthcare, life sciences, media and telecommunications. For more information, please visit www.luxoft.com .
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .
All information set out in the materials is provided in good faith but does not form part of or constitute an offer or contract. Statements, figures, plans, views and representations are for presentation purposes and indicative only. Luxoft has made reasonable efforts to include accurate information, wherever possible. However, Luxoft makes no warranties or representations, expressed or implied, as to the completeness of the information provided. Luxoft will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in these materials .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200102005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release
First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an
Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release
Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
